Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 9;7(8):e723.
doi: 10.1097/TXD.0000000000001176. eCollection 2021 Aug.

Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance

Nabeel Aslam  1 , Christopher L Trautman  1 , Taimur Sher  2
Affiliations
Review

Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance

Nabeel Aslam et al. Transplant Direct. .

Abstract

Plasma cell disorders are one of the most common hematologic malignancies. Monoclonal gammopathy of undetermined significance (MGUS) is defined by a serum monoclonal protein <3 g/dL, bone marrow plasma cell infiltration <10%, and most importantly absence of end-organ damage. The prevalence of MGUS in general population is estimated to be 1%-4% and its frequency increases with age with 3% among people above 50 y of age. The risk of progression to clinically significant plasma cell dyscrasia is estimated to be 1% per year. With aging population and increasing use of transplantation for the management of kidney disease in older adults, MGUS is being identified during the evaluation for kidney transplant candidacy or during the postkidney transplant follow-up. MGUS in patients with end-stage renal disease (ESRD) undergoing evaluation for kidney transplant can pose a complex management dilemma. In this article, we review the current state of knowledge about the prevalence of MGUS in ESRD population and the impact of kidney transplantation on the progression of MGUS to clinically significant plasma cell disorder. We make recommendations for the screening of ESRD patients undergoing kidney transplant evaluation and the management of MGUS after renal transplant.

PubMed Disclaimer

Conflict of interest statement

The authors declare no funding or conflicts of interest.

Figures

None
Graphical abstract
FIGURE 1.
FIGURE 1.
Recommended algorithm for the pretransplant evaluation. FLC, free light chain; SPEP, serum protein electrophoresis.
See this image and copyright information in PMC

References

    1. Barlogie B, Alexanian R, Jagannath S. Plasma cell dyscrasias. JAMA. 1992; 268:2946–2951. - PubMed
    1. Doshi M, Lahoti A, Danesh FR, et al. ; American Society of Nephrology Onco-Nephrology Forum. Paraprotein-related kidney disease: kidney injury from paraproteins-what determines the site of injury? Clin J Am Soc Nephrol. 2016; 11:2288–2294. - PMC - PubMed
    1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. . International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014; 15:e538–e548. - PubMed
    1. Kyle RA, Therneau TM, Rajkumar SV, et al. . Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006; 354:1362–1369. - PubMed
    1. Wolfe RA, Ashby VB, Milford EL, et al. . Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999; 341:1725–1730. - PubMed